Google
ANL — ADLAI NORTYE LTD. AMERICAN DEPOSITARY SHARES (Healthcare >> Biotechnology)
ANL FAQ
What is ANL's ROE?
ADLAI NORTYE LTD. AMERICAN DEPOSITARY SHARES reports a Return on Equity (ROE) of 649.66%.
What is ANL's dividend yield?
ADLAI NORTYE LTD. AMERICAN DEPOSITARY SHARES offers a dividend yield of 0.00%.
What is ANL's Deepscope Quality Score?
Deepscope rates ANL's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ANL?
Deepscope's AI Timing Score for ANL is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ANL belong to?
ADLAI NORTYE LTD. AMERICAN DEPOSITARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.95
Price
-1.05
(-9.55%)
Day Change
|
|
|---|
ANL, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.95 |
| PBV / Sector |
-87.13 / 4.63
|
| Earning Per Share | -0.74 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.70 M
GREAT
|
| Average 1W Daily Value |
1.55 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | ANL |
| Name | ADLAI NORTYE LTD. AMERICAN DEPOSITARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 58.73 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 725.12 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: New Jersey Biotechnology Dev Ctr, North Brunswick, NJ, United States, 08902
Phone: 848 230 7430
Website: https://www.adlainortye.com
Employees: 109
Sector: Healthcare >> Biotechnology
Description: Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
